Company
Axsome
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
2
2 still marketed
Novel approvals
0
Approvals since 2021
3
Originals and new uses
Phase 3 trials
28
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
- Phase 328
Recent approvals
Originals and efficacy supplements, newest first.
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT)Pivotal-lookingRecruiting
Axsome Therapeutics, Inc.Industry
NCT07766655 · 705 participants (planned) · Start Aug 27, 2026 · Primary completion Dec 2027
Drug: AXS-05 (dextromethorphan-bupropion); Bupropion and 1 more · For: Smoking Cessation
Sites: Phoenix, Arizona; Little Rock, Arkansas; Lemon Grove, California · 28 sites in all
- Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research DesignPivotal-lookingRecruiting
Axsome Therapeutics, Inc.Industry
NCT07398417 · 620 participants (planned) · Start Jan 14, 2026 · Primary completion Mar 2028
Drug: AXS-14 (Esreboxetine); Placebo · For: Fibromyalgia
Sites: Glendale, Arizona; Phoenix, Arizona; Tucson, Arizona · 57 sites in all
- Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)Pivotal-lookingRecruiting
Axsome Therapeutics, Inc.Industry
NCT06568367 · 520 participants (planned) · Start Aug 1, 2024 · Primary completion Dec 2026
Drug: Solriamfetol 150 mg; Solriamfetol 300 mg and 1 more · For: Excessive Sleepiness; Shift-work Disorder
Sites: Auburn, Alabama; Cullman, Alabama; Chandler, Arizona · 49 sites in all
- Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using SolriamfetolPivotal-lookingRecruiting
Axsome Therapeutics, Inc.Industry
NCT07484217 · 508 participants (planned) · Start Feb 23, 2026 · Primary completion Dec 2028
Drug: Solriamfetol 150 MG; Placebo · For: Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Sites: Tucson, Arizona; Bellflower, California; Chino, California · 40 sites in all
- Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)Pivotal-lookingRecruiting
Axsome Therapeutics, Inc.Industry
NCT07717892 · 468 participants (planned) · Start Jun 25, 2026 · Primary completion Jun 30, 2028
Drug: Solriamfetol Dose A; Solriamfetol Dose B and 1 more · For: ADHD
Sites: Dothan, Alabama; Little Rock, Arkansas; Anaheim, California · 31 sites in all
- Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)Pivotal-lookingRecruiting
Axsome Therapeutics, Inc.Industry
NCT07717879 · 468 participants (planned) · Start Jul 6, 2026 · Primary completion Jun 30, 2028
Drug: Solriamfetol Dose A; Solriamfetol Dose B and 1 more · For: ADHD
Sites: Dothan, Alabama; Little Rock, Arkansas; Anaheim, California · 32 sites in all
- Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using SolriamfetolPivotal-lookingRecruiting
Axsome Therapeutics, Inc.Industry
NCT06413433 · 450 participants (planned) · Start Apr 26, 2024 · Primary completion Dec 2026
Drug: Solriamfetol 150 mg; Solriamfetol 300 mg and 1 more · For: Binge-Eating Disorder
Sites: Encino, California; Garden Grove, California; Long Beach, California · 45 sites in all
Marketed drugs (2)
Newest FDA action first.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.